Evaluation of Membrane Phospholipid and Energy Metabolism in Subjects at High Risk of Psychotic Transition
- Conditions
- Patients With Ultra High Risk of Psychotic Transition
- Registration Number
- NCT05865652
- Lead Sponsor
- Centre Hospitalier Henri Laborit
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 22
Inclusion Criteria for the UHR group:<br><br> - Patient between 15 and 25 years old<br><br> - Patient fulfilling the UHR criteria objectified by the Comprehensive Assessment of<br> At Risk Mental State scale (CAARMS) and by the social and professional functioning<br> assessment scale (SOFAS) (the Vulnerability group is also taken into account,<br> combining first-degree history and functional impact.)<br><br> - Patient with no contraindication to performing a 7T MRI examination<br><br> - Affiliated patient or beneficiary of a social security scheme.<br><br> - Free, informed consent, written and signed by the participant, the investigator and<br> the legal representative if applicable (at the latest on the day of inclusion and<br> before any examination required by the research).<br><br>Inclusion Criteria for the Control group:<br><br> - Subjects aged 15 to 25 years old,<br><br> - healthy volunteer subject or subject to benefit from an imaging examination, not<br> presenting the criteria of a mental health disorder objectified by a medical<br> interview<br><br> - Subject with no contraindication to performing a 7T MRI examination<br><br> - Affiliated subject or beneficiary of a social security scheme.<br><br> - Free, informed and written consent signed by the participant, the investigator and<br> the legal representative if applicable (at the latest on the day of inclusion and<br> before any examination required by the research).<br><br>Exclusion Criteria for the UHR group:<br><br> - Patient not at risk or already in a psychotic pathological process according to<br> DSM-5 criteria.<br><br> - Patient already receiving antipsychotic treatment or whose background treatment was<br> changed less than a month ago.<br><br> - Patient presenting an absolute contraindication to 7T MRI such as: foreign bodies<br> (intracranial clips, vascular magnetic clips, cardiac or neural pacemakers, stents,<br> coils, implantable chamber, intracorporeal metallic splinters, cochlear implants,<br> intracorporeal metallic foreign bodies, mechanical heart valve, implanted injection<br> pump, non-removable piercings), pregnant woman, allergy to contrast products,<br> moderate to severe renal insufficiency, breastfeeding, implanted contraception,<br> tinnitus, claustrophobia and braces.<br><br>The relative contraindications are to be considered, namely: previous surgical<br>interventions, medically implanted device, tattoo or permanent make-up.<br><br>Exclusion criteria for the control group:<br><br> - Subject presenting an absolute contraindication to 7T MRI such as: foreign bodies<br> (intracranial clips, vascular magnetic clips, cardiac or neural pacemakers, stents,<br> coils, implantable chamber, intracorporeal metallic fragments, cochlear implants,<br> intracorporeal metallic foreign bodies, valve mechanical heart, implanted injection<br> pump, non-removable piercings), pregnant woman, allergy to contrast products,<br> moderate to severe renal insufficiency, breast-feeding, implanted contraception,<br> tinnitus, claustrophobia and braces.<br><br>The relative contraindications are to be considered, namely: previous surgical<br>interventions, medically implanted device, tattoo or permanent make-up.
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Difference of cellular inorganic phosphate between UHR-T and UHR-NT patients.;Difference of cellular phosphocreatine between UHR-T and UHR-NT patients.;Difference of cellular Gamma ATP between UHR-T and UHR-NT patients.;Difference of cellular Alpha ATP between UHR-T and UHR-NT patients.;Difference of cellular beta ATP between UHR-T and UHR-NT patients.;Difference of intracellular pH between UHR-T and UHR-NT patients.;Difference of membrane phosphodiester alterations between UHR-T and UHR-NT patients.;Difference of membrane phosphomonoester alterations between UHR-T and UHR-NT patients.
- Secondary Outcome Measures
Name Time Method Difference of cellular inorganic phosphate between UHR subjects and control subjects.;Difference of cellular phosphocreatine between UHR subjects and control subjects.;Difference of cellular Gamma ATP between UHR subjects and control subjects.;Difference of cellular Alpha ATP between UHR subjects and control subjects.;Difference of cellular beta ATP between UHR subjects and control subjects.;Difference of cellular intracellular pH between UHR subjects and control subjects.;Difference of membrane phosphodiester alterations between UHR subjects and control subjects.;Difference of membrane phosphomonoester alterations between UHR subjects and control subjects.